Old Web
English
Sign In
Acemap
>
authorDetail
>
C. Hartman
C. Hartman
Erasmus University Medical Center
Medicine
Placebo
Progressive disease
Pathology
Discontinuation
3
Papers
75
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).
2011
Journal of Clinical Oncology
Mark J. Ratain
Gary K. Schwartz
Amit M. Oza
C. M. Rudin
Stanley B. Kaye
M.J.A. de Jonge
D. Khayat
Ahmad Awada
Michael B. Sawyer
J. C. Obel
J. Medioni
T. R. J. Evans
J.-P. De Greve
Patricia M. M. B. Soetekouw
J. Baurain
P.J. O'Dwyer
C. Hartman
V. Poulart
Ian Walters
Show All
Source
Cite
Save
Citations (22)
Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.
2011
Journal of Clinical Oncology
Gary K. Schwartz
R. G. Maki
Mark J. Ratain
Samir D. Undevia
Robin L. Jones
Charles M. Rudin
Lillian L. Siu
Bruce Brockstein
D. Khayat
T Gil
M.J.A. de Jonge
Michael B. Sawyer
T. R. J. Evans
J. Medioni
P.J. O'Dwyer
C. Hartman
V. Poulart
Ian Walters
Show All
Source
Cite
Save
Citations (19)
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
2004
European Journal of Cancer
O. Soepenberg
Alex Sparreboom
M.J.A. de Jonge
A.S.Th. Planting
G. de Heus
W. J. Loos
C. Hartman
C. Bowden
Jaap Verweij
Show All
Source
Cite
Save
Citations (34)
1